Dr. Slovin on the Role of Immunotherapy for Prostate Cancer

Video

In Partnership With:

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Prostate cancer was among the first solid tumor to have a positive experience with immune-based therapy, Slovin explains. For the last 30 years, there has been a variety of different platforms of immunotherapy including vaccine and viral vectors, none of which showed any impact for patients with prostate cancer.

The FDA approval of sipuleucel-T (Provenge) represented the first successful immunotherapy for a solid tumor that showed a survival benefit. All approaches that have been done subsequently are attempting to look at other ways of using the body’s immune system to fight cancer, states Slovin.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,